Crossmark

Double or Triple Antithrombotic Treatment in Atrial Fibrillation Patients with Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention

Crossref DOI link: https://doi.org/10.1007/s40256-020-00403-3

Published Online: 2020-03-14

Published Print: 2021-01

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Benetou, Despoina-Rafailia

Varlamos, Charalampos

Mpahara, Aikaterini

Alexopoulos, Dimitrios
License Information

Text and Data Mining valid from 2020-03-14

Version of Record valid from 2020-03-14
More Information

Article History

First Online: 14 March 2020

Compliance with Ethical Standards

:

: No sources of funding were used to assist with the preparation of this review.

: Dr. Alexopoulos has received lecturing honoraria/advisory board fees from AstraZeneca, Bayer, Boehringer Ingelheim, Pfizer, Medtronic, Biotronik, and Chiesi Hellas. Despoina-Rafailia Benetou, MD, Charalampos Varlamos, MD, and Aikaterini Mpahara, MD, have no conflicts of interest that are directly relevant to the content of this review.

Document is current

Any future updates will be listed below